<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636909</url>
  </required_header>
  <id_info>
    <org_study_id>2001P002293</org_study_id>
    <secondary_id>W-99-0234-FB</secondary_id>
    <nct_id>NCT00636909</nct_id>
  </id_info>
  <brief_title>Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders</brief_title>
  <acronym>MINI HEME</acronym>
  <official_title>Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide allogeneic stem cell transplantation to patients who
      have not traditionally undergone this procedure because of it high incidence of treatment
      related side effects. We hope to decrease these side effects by decreasing the chemotherapy
      dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone
      marrow is not completely eliminated) and by using donated stem cells to treat cancer of the
      blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>durable engraftment</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hematopoeitic reconstitution</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate the patterns of post-transplant chimerism among lymphoid and antigen presenting cells</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival and overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment related toxicity and acute and chronic graft versus host disease</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>CML Chronic Phase, Accelerated Phase, or Blast Crisis</condition>
  <condition>CLL</condition>
  <condition>MDS</condition>
  <condition>RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA</condition>
  <condition>APLASTIC ANEMIA</condition>
  <condition>MULTIPLE MYELOMA</condition>
  <condition>MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment arm with G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>preparative cytoreduction</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
    <description>preparative cytoreduction</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>immunosuppressive therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>immunosuppressive therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>foster engraftment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Patient:

          -  AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED
             NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma,
             MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET

          -  Age less than 65 years

          -  Patients must have a healthy family member who is HLA-identical to the recipient or
             has 1 antigen mismatch and who is willing to receive a course of G-CSF and undergo 2-4
             daily leukaphereses

          -  Each patient must sign an informed consent and be willing to participate as a research
             subject after having been advised of the nature and risk of the study prior to
             entering protocol

        Inclusion Criteria - Donor:

          -  Absence of hematologic or marrow function related diseases that interferes with the
             collection of sufficient numbers of normal progenitor cells

          -  Absence of any medical condition that would pose a serious health risk by undergoing
             peripheral blood stem cell harvest

          -  Negative HIV, HTLV-1, Hepatitis B surface antigen and Hepatitis C

          -  The donor must be blood relation. A prospective related donor must be at least
             genotypically HLA-A, B, DR identical to the patient, but can differ for 1 HLA-locus.

        Exclusion Criteria - Patient:

          -  Active CNS involvement

          -  Females who are pregnant or breast feeding

          -  ECOG performance status &gt; 1. Karnofsky performance status &lt; 80%

          -  LVEF &lt; 40%

          -  Active viral, bacterial, or fungal infection

          -  Patients seropositive for HIV; HTLV -1

          -  Patients not providing informed consent

          -  Patients with known hypersensitivity to E. Coli derived product

        Exclusion Criteria - Donor:

          -  A positive HIv infection or HTLV - 1 test or evidence of active/persistent viral
             hepatitis infection. Presence of any medical condition that would pose a serious
             health risk by undergoing peripheral blood stem cell harvest. Donors with known
             hypersensitivity to E. Coli derived products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F McDermott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David E Avigan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>David McDermott</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>CML</keyword>
  <keyword>CLL</keyword>
  <keyword>MDS</keyword>
  <keyword>NHL</keyword>
  <keyword>HODGKIN'S LYMPHOMA</keyword>
  <keyword>APLASTIC ANEMIA</keyword>
  <keyword>MULTIPLE MYELOMA</keyword>
  <keyword>MYELOPROLIFERATIVE DISORDER</keyword>
  <keyword>ALLOGENEIC</keyword>
  <keyword>STEM CELL TRANSPLANT</keyword>
  <keyword>HEMATOLOGIC DISORDERS</keyword>
  <keyword>CYCLOPHOSPHAMIDE</keyword>
  <keyword>FLUDARABINE</keyword>
  <keyword>CYCLOSPORINE</keyword>
  <keyword>METHOTREXATE</keyword>
  <keyword>G-CSF</keyword>
  <keyword>GVHD</keyword>
  <keyword>ENGRAFTMENT</keyword>
  <keyword>CHIMERISM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

